Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients

Annals of Oncology

Volumn 22, Issue 1, 2011, Pages 234-235

  Ruzzo, A ^a   Canestrari, E ^a   Galluccio, N ^a   Santini, D ^b   Vincenzi, B ^b   Tonini, G ^b   Magnani, M ^a   Graziano, F ^c  

^a UNIVERSITY OF URBINO   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c SAN SALVATORE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IRINOTECAN; PANITUMUMAB;

CLINICAL TRIAL; COLORECTAL CANCER; DRUG RESPONSE; GENE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; KRAS GENE; LETTER; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 78650384736     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq472     Document Type: Letter

References (6)

1. Zhang W, Winder T, Ning YHJ et al. A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wildtype KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol 2011; 22: 104-109.
2. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26(35): 5705-5712.
3. Loupakis F, Ruzzo A, Cremolini C et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101(4): 715-721.
4. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361(1): 98-99.
5. Graziano F, Canestrari E, Loupakis F et al. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics J 2010 Feb 23. [Epub ahead of print].
6. Winder T, Zhang W, El-Khoueiry A et al. Association of a germ-line variant in the K-ras 3' untranslated region with response and progression-free survival in patients with mCRC treated with single-agent cetuximab (IMCL-0144) or in combination with cetuximab (EPIC) independent of K-ras mutation status. J Clin Oncol, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2009; 27 (15S Suppl): 4061.